Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Kevin H.M. Kuo, Pranee Sutcharitchan, Ping Chong Bee, Lee Ping Chew, Soo Min Lim, Ai Sim Goh, Sadanand Vodala, Wen-Ling Kuo, Yinzhi Lai, Loyse Felber Medlin, Martina Perin, Luciana Moro Bueno, Thomas D Coates, Vip Viprakasit

Blood (2023) 142 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2023-174082

Published: 2023

Journal Articles

Physical Activities in Patients with β-Thalassemia As Measured By Fitbit in Association with Patient-Reported Outcomes

Antonis Kattamis, MD, Pranee Sutcharitchan, MD, Ali Taher, MDPhDFRCP, Maria Domenica Cappellini, MD, Dalia Mahmoud, Joseph Pariseau, PharmD, Abderrahmane Laadem, MD, Anzalee Khan, PhD, X. Henry Hu, MD PhD, Vip Viprakasit, MD PhD

Blood (2017) 130 (Supplement 1): 4731.

https://doi.org/10.1182/blood.V130.Suppl_1.4731.4731

Published: 2017

Journal Articles

Quality of Life in Patients with β-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent

Maria Domenica Cappellini, MD, Antonis Kattamis, MD, Vip Viprakasit, MD PhD, Pranee Sutcharitchan, MD, Dalia Mahmoud, Joseph Pariseau, PharmD, Abderrahmane Laadem, MD, Anzalee Khan, PhD, X. Henry Hu, MD PhD, Ali Taher, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 751.

https://doi.org/10.1182/blood.V130.Suppl_1.751.751

Published: 2017

Journal Articles

Vascular and Hemostatic Alterations Associated with Pulmonary Hypertension in β-Thalassemia Hemoglobin E Patients Receiving Regular Transfusion and Iron Chelation

Noppacharn Uaprasert, MB, BCH, Sudarat Satitthummanid, MD MSc, Benjaporn Akkawat, BSc, Pranee Sutcharitchan, MD, Ponlapat Rojnuckarin, MD PhD

Blood (2017) 130 (Supplement 1): 1029.

https://doi.org/10.1182/blood.V130.Suppl_1.1029.1029

Published: 2017

Journal Articles

An Effective Screening Algorithm and a Simple DNA Sequencing Protocol for Molecular Characterization of Rare Alpha-Globin Variants

Noppacharn Uaprasert, MD, Rung Settapiboon, Supaporn Amornsiriwat, Pranee Sutcharitchan, MD, Ponlapat Rojnuckarin, MD PhD

Blood (2015) 126 (23): 2081.

https://doi.org/10.1182/blood.V126.23.2081.2081

Published: 2015

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Ali T. Taher, John Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini

Blood (2012) 120 (5): 970–977.

https://doi.org/10.1182/blood-2012-02-412692

Published: 2012

Includes: Supplemental data

Journal Articles

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Ali T Taher, MD, John B. Porter, MD, Vip Viprakasit, MD; DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppodol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Jacqueline Ros, PhD, Yiyun Zhang, Dany Habr, MD, M. Domenica Cappellini, MD

Blood (2011) 118 (21): 902.

https://doi.org/10.1182/blood.V118.21.902.902

Published: 2011

Journal Articles

Diagnostic Utility of Isoelectric Focusing and High Performance Liquid Chromatography in Fetal Cord Blood Screening for Thalassemia and Non-Sickling Hemoglobinopathies,

Noppacharn Uaprasert, MD, Rung Settapiboon, Supaporn Amornsiriwat, Patsita Sarnthammakul, Ponlapat Rojnuckarin, MD, PhD, Pranee Sutcharitchan, MD

Blood (2011) 118 (21): 4202.

https://doi.org/10.1182/blood.V118.21.4202.4202

Published: 2011

Journal Articles

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Saleh Elalfy, Pranee Sutcharitchan, Chi-Kong Li, Hishamshah Ibrahim, Vip Viprakasit, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2010) 115 (12): 2364–2371.

https://doi.org/10.1182/blood-2009-04-217455

Published: 2010

Journal Articles

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

M. Domenica Cappellini, Mohsen Saleh Elalfy, Amal El-Beshlawy, Antonis Kattamis, Lee Lee Chan, ChunFu Li, Kai-Hsin Lin, Giovanni Quarta, Pranee Sutcharitchan, Ali Taher, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter

Blood (2009) 114 (22): 5107.

https://doi.org/10.1182/blood.V114.22.5107.5107

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Dudley Pennell, Pranee Sutcharitchan, Amal El-Beshlawy, Yesim Aydinok, Ali Taher, Gillian Smith, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, John B Porter

Blood (2008) 112 (11): 3874.

https://doi.org/10.1182/blood.V112.11.3874.3874

Published: 2008

NARROW

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Physical Activities in Patients with β-Thalassemia As Measured By Fitbit in Association with Patient-Reported Outcomes

Quality of Life in Patients with β-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent

Vascular and Hemostatic Alterations Associated with Pulmonary Hypertension in β-Thalassemia Hemoglobin E Patients Receiving Regular Transfusion and Iron Chelation

An Effective Screening Algorithm and a Simple DNA Sequencing Protocol for Molecular Characterization of Rare Alpha-Globin Variants

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Diagnostic Utility of Isoelectric Focusing and High Performance Liquid Chromatography in Fetal Cord Blood Screening for Thalassemia and Non-Sickling Hemoglobinopathies,

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only